Spero Therapeutics/$SPRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Spero Therapeutics
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Ticker
$SPRO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
ISIN
US84833T1034
Website
SPRO Metrics
BasicAdvanced
$140M
-
-$1.28
-
-
Price and volume
Market cap
$140M
52-week high
$2.80
52-week low
$0.51
Average daily volume
7.2M
Financial strength
Current ratio
2.563
Quick ratio
2.51
Long term debt to equity
6.403
Total debt to equity
11.711
Management effectiveness
Return on assets (TTM)
-37.21%
Return on equity (TTM)
-107.28%
Valuation
Price to revenue (TTM)
3.056
Price to book
4.13
Price to tangible book (TTM)
4.13
Price to free cash flow (TTM)
-4.081
Growth
Revenue change (TTM)
-59.83%
Earnings per share change (TTM)
-393.39%
3-year revenue growth (CAGR)
50.71%
3-year earnings per share growth (CAGR)
-26.74%
What the Analysts think about SPRO
Analyst ratings (Buy, Hold, Sell) for Spero Therapeutics stock.
SPRO Financial Performance
Revenues and expenses
SPRO Earnings Performance
Company profitability
SPRO News
AllArticlesVideos
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
Benzinga·5 days ago
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
GlobeNewsWire·5 days ago
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Spero Therapeutics stock?
Spero Therapeutics (SPRO) has a market cap of $140M as of June 02, 2025.
What is the P/E ratio for Spero Therapeutics stock?
The price to earnings (P/E) ratio for Spero Therapeutics (SPRO) stock is 0 as of June 02, 2025.
Does Spero Therapeutics stock pay dividends?
No, Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders as of June 02, 2025.
When is the next Spero Therapeutics dividend payment date?
Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Spero Therapeutics?
Spero Therapeutics (SPRO) does not currently have a Beta indicator.